ReviewCancer medicine2021
Enhancement of tumor lethality of ROS in photodynamic therapy.
Review in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 121 citations in OpenAlex.
- Algae-Integrated Optoelectronic Nanoplatform for Tumor Hypoxia Relief and Enhanced Photodynamic Therapy.Advanced healthcare materials · 2026Article
- Identification and characterization of phyllochlorin sodium as a novel chlorin-derived photosensitiser.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- Liposome-Based Photodynamic Therapy for Breast Cancer: Innovations in Targeted Delivery, Combination Strategies, and Clinical Translation.International journal of molecular sciences · 2026Review
- MnOPharmaceutics · 2026Article
- Engineered MoSNanomaterials (Basel, Switzerland) · 2026Review
- Enhanced Sonodynamic Therapy and Radiotherapy Efficacy: Modified Polyethylene Glycol-Bismuth Trioxide Nanoplatform for Targeted Tumor Treatment.Biomaterials research · 2026Article
- Tailoring Advanced Metal-Based Nanomedicines for Adaptable Nanodynamic Disease Therapies and Theranostics.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Advancing Photodynamic Cancer Therapy with Smart Light-Responsive Lipid and Polymeric Nanocarriers: Evidence from a Meta-Analysis of Efficacy and Pharmacokinetics.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity.Cancer biology & medicine · 2025Article
- Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy.Small science · 2025Article
- Hyaluronic Acid-Functionalized Bismuth Vanadate/Molybdenum Disulfide Nanoheterojunctions Achieve Efficient Phototherapy of Hypoxic Tumor.Biomaterials research · 2025Article
- Graphene-Based Nanomaterials in Photodynamic Therapy: Synthesis Strategies, Functional Roles, and Clinical Translation for Tumor Treatment.International journal of nanomedicine · 2025Review
- Photodynamic therapy and nanomedicine: current knowledge, limitations, and applications in oral squamous cell carcinoma: a narrative review.Frontiers in oncology · 2025Review
- Advances in smart nanotechnology-supported photodynamic therapy for cancer.Cell death discovery · 2024Review
- Multifunctional gold nanoparticles for cancer theranostics.3 Biotech · 2024Review
- Recent Progress in Photothermal, Photodynamic and Sonodynamic Cancer Therapy: Through the cGAS-STING Pathway to Efficacy-Enhancing Strategies.Molecules (Basel, Switzerland) · 2024Review
- Article
- Surufatinib combined with photodynamic therapy induces ferroptosis to inhibit cholangiocarcinomaFrontiers in pharmacology · 2024Article
- Combined Ferritin Nanocarriers with ICG for Effective Phototherapy Against Breast Cancer.International journal of nanomedicine · 2024Article
- Therapeutic applications of carbon nanomaterials in renal cancer.Biotechnology letters · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the process of photodynamic therapy (PDT) treatment of tumors, reactive oxygen species (ROS) plays a key role in destroying tumor tissues. However, traditional PDT often has limited ROS killing capacity due to hypoxia in the tumor microenvironment (TME) or obstruction by the ROS defense system, resulting in poor efficacy. Therefore, enhancing the killing effect of ROS on tumors is the core of enhancing the anti-tumor effect of PDT. In recent years, many studies have developed a series of strategies to enhance the ability of ROS to kill tumors in view of the limitations of the TME on PDT. This article summarizes the commonly used or innovative strategies in recent years, including not only frequently used methods for hypoxia in the TME but also innovative strategies to inhibit the ROS defense system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.